GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump
Newer Drugs Fuel HIV Sales Growth
Executive Summary
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.
You may also be interested in...
Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
European Approval For Roxadustat Is Silver Lining For FibroGen
The EU approval is good news for FibroGen and marketing partner Astellas, but was expected, and still leaves it pondering its future after FDA knock-back.
GSK Exceeds Expectations In Q2, But Still Awaiting Shingrix Bounce Back
While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.